Retatrutide, from Soma Pharmaceuticals , is receiving significant attention as a novel therapy for obesity management . This dual-action drug combines the mechanism of a GLP-1 receptor activator and a GIP receptor stimulant, designed to effectively promote reduced body fat but also improve associated metabolic factors. Early patient trials have … Read More